m6A-centered Crosstalk Information

Mechanism of Crosstalk between m6A Modification and Epigenetic Regulation

m6A Modification:
Crosstalk ID	M6ACROT00186				[1], [2], [3]
m⁶A modification ADAR1 ADAR1 METTL3 Methylation : m⁶A sites Direct Enhancement RNA modification MIR200B MIR200B ADAR Methylation : modification sites
m6A Regulator	Methyltransferase-like 3 (METTL3)			WRITER	Regulator Info
m6A Target	Interferon-inducible protein 4 (ADAR1)				Targert Gene
Epigenetic Regulation that have Cross-talk with This m6A Modification:
Epigenetic Regulation Type	RNA modification (RNAMod) >> Adenosine-to-Inosine editing (A-to-I)
Epigenetic Regulator	Interferon-inducible protein 4 (ADAR1)			WRITER	View Details
Regulated Target	microRNA 200b (MIR200B)				View Details
Crosstalk Relationship	m6A → A-to-I			Enhancement
Crosstalk Mechanism	m6A modification directly impacts RNA modification through modulating the expression level of RNA modification regulator
Crosstalk Summary	METTL3 methylates Interferon-inducible protein 4 (ADAR1) mRNA, thereby enhancing its protein expression, which subsequently promotes ADAR mediated A-to-I RNA editing of the MicroRNA 200b (MIR200B) transcript.
Pathway Response	mRNA surveillance pathway				hsa03015
Pathway Response	RNA degradation				hsa03018
Cell Process	RNA stability
In-vitro Model	MGG8	Glioblastoma	Homo sapiens		CVCL_D1H4
	U-87MG ATCC	Glioblastoma	Homo sapiens		CVCL_0022
	U-118MG	Astrocytoma	Homo sapiens		CVCL_0633
	CAL-62	Thyroid gland anaplastic carcinoma	Homo sapiens		CVCL_1112
	TPC-1	Thyroid gland papillary carcinoma	Homo sapiens		CVCL_6298

References

Ref 1	N?-Methyladenosine Landscape of Glioma Stem-Like Cells: METTL3 Is Essential for the Expression of Actively Transcribed Genes and Sustenance of the Oncogenic Signaling. Genes (Basel). 2019 Feb 13;10(2):141. doi: 10.3390/genes10020141.
Ref 2	ADAR1 is a new target of METTL3 and plays a pro-oncogenic role in glioblastoma by an editing-independent mechanism. Genome Biol. 2021 Jan 28;22(1):51. doi: 10.1186/s13059-021-02271-9.
Ref 3	ADAR1-mediated RNA editing is a novel oncogenic process in thyroid cancer and regulates miR-200 activity. Oncogene. 2020 Apr;39(18):3738-3753. doi: 10.1038/s41388-020-1248-x. Epub 2020 Mar 10.